WallStSmart
ILMN

Illumina Inc

NASDAQ: ILMN · HEALTHCARE · DIAGNOSTICS & RESEARCH

$126.74
+5.29% today

Updated 2026-04-30

Market cap
$18.29B
P/E ratio
22.09
P/S ratio
4.21x
EPS (TTM)
$5.45
Dividend yield
—
52W range
$74 – $156
Volume
1.6M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Illumina Inc (ILMN) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$126.74
Consensus
$124.00
-2.16%
2030 Target
$536.51
+323.32%
DCF
$294.98
+60.55% MoS
24 analysts:
4 Buy9 Hold4 Sell

Management guidance

Illumina provided FY2026 guidance of 4-6% organic revenue growth ex-China (implying total revenue of $4.51B-$4.63B) with adjusted EPS of $5.05-$5.20. Management highlighted NovaSeq X platform adoption, clinical consumables momentum (20% growth ex-China in Q4 2025), and SomaLogic acquisition integration as key drivers for sustained growth through 2026-2027.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$881.41
$6.8B Rev × 20x P/S
Base case (2030)
$536.51
$6.8B Rev × 12x P/S
Bear case (2030)
$357.67
$6.8B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$4.5B$4.4B$4.3B$4.6B$5.0B$5.5B$6.1B$6.8B
Revenue growth—-2.9%-0.7%6.5%8.4%9.5%10.4%11.5%
EPS$0.87$2.45$4.85$5.12$6.15$7.25$8.65$10.35
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$357.67$395.99$434.32$472.64$536.51

Catalysts & risks

Growth catalysts
+ NovaSeq X platform transition completion and adoption acceleration through 2026-2027
+ China market reopening (ban on DNA sequencer imports lifted in March 2026)
+ SomaLogic proteomics integration driving multiomics revenue expansion
+ Labcorp and preventive genomics partnership scaling precision oncology testing
+ Clinical consumables segment sustaining 15-20% growth ex-China
+ Margin expansion from operating leverage as SomaLogic integrates
Key risks
- Slowdown in research segment demand and genomics market recovery pace uncertainty
- NovaSeq X transition friction and customer adoption delays extending into 2027
- China market re-entry execution risk and competitive dynamics post-ban lift
- SomaLogic integration complexity and near-term EPS dilution persisting longer than expected
- Regulatory scrutiny related to historical Grail acquisition and divestiture
- Competitive pressure from PacBio and other genomics platforms in sequencing market

Methodology

Illumina Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 24 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.